[1]苏 凝,樊利萍,秦丽丽,等.恩度联合顺铂胸腔内灌注治疗非小细胞肺癌恶性胸腔积液的疗效[J].医学信息,2021,34(11):155-157.[doi:10.3969/j.issn.1006-1959.2021.11.043]
　SU Ning,FAN Li-ping,QIN Li-li,et al.Efficacy of Endu Combined with Cisplatin Intrapleural Perfusion in the Treatment of Non-small Cell Lung Cancer with Malignant Pleural Effusion[J].Medical Information,2021,34(11):155-157.[doi:10.3969/j.issn.1006-1959.2021.11.043]
点击复制

恩度联合顺铂胸腔内灌注治疗非小细胞肺癌恶性胸腔积液的疗效()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
34卷
期数:
2021年11期
页码:
155-157
栏目:
药物与临床
出版日期:
2021-06-01

文章信息/Info

Title:
Efficacy of Endu Combined with Cisplatin Intrapleural Perfusion in the Treatment of Non-small Cell Lung Cancer with Malignant Pleural Effusion
文章编号:
1006-1959（2021）11-0155-03
作者:
苏 凝; 樊利萍; 秦丽丽; 等
（晋城市人民医院呼吸与危重症医学科，山西 晋城 048000）
Author(s):
SU Ning; FAN Li-ping; QIN Li-li; et al.
(Department of Respiratory and Critical Care Medicine,Jincheng People’s Hospital,Jincheng 048000,Shanxi,China)
关键词:
恩度; 顺铂; 胸腔内灌注; 非小细胞肺癌; 恶性胸腔积液
Keywords:
Endo; Cisplatin; Intrapleural perfusion; Non-small cell lung cancer; Malignant pleural effusion
分类号:
R734.2
DOI:
10.3969/j.issn.1006-1959.2021.11.043
文献标志码:
A
摘要:
目的 分析恩度联合顺铂胸腔内灌注治疗非小细胞肺癌恶性胸腔积液的疗效。方法 选取2018年6月~2020年9月我院收治的60例非小细胞肺癌恶性胸腔积液患者作为研究对象，按照随机数字表法分为观察组和对照组，各30例。对照组予以顺铂治疗，观察组在对照组基础上联合恩度治疗，比较两组临床疗效、健康状况、胸腔积液血管内皮生长因子（VEGF）、低氧诱导因子-1（HIF-1α）水平及不良反应发生情况。结果 观察组ORR率、DCR率均高于对照组（76.67% vs 40.00%）、（93.33% vs 66.67%），差异有统计学意义（P＜0.05）。观察组KPS评分高于对照组[（83.45±6.14）分 vs（76.58±6.85）分]，差异有统计学意义（P＜0.05）。观察组VEGF、HIF-1α低于对照组，差异有统计学意义（P＜0.05）。两组不良反应发生率比较，差异无统计学意义（P＞0.05）。结论 恩度联合顺铂胸腔内灌注治疗非小细胞肺癌恶性胸腔积液近期疗效确切，能够有效消除患者胸腔积液，提高患者生活自理能力，且无严重不良反应。
Abstract:
Objective To analyze the efficacy of Endo combined with cisplatin intrapleural perfusion in the treatment of malignant pleural effusion of non-small cell lung cancer.Methods 60 patients with malignant pleural effusion of non-small cell lung cancer who were admitted to our hospital from June 2018 to September 2020 were selected as the research objects. According to the random number table method, they were divided into a observation group and a control group, with 30 cases in each group.The control group was treated with cisplatin, and the observation group was treated with Endo on the basis of the control group.The clinical efficacy, health status, pleural effusion vascular endothelial growth factor (VEGF), hypoxia inducible factor-1 (HIF-1α) levels and the occurrence of adverse reactions were compared between the two groups.Results The ORR rate and DCR rate of the observation group were higher than those of the control group (76.67% vs 40.00%) and (93.33% vs 66.67%),the difference was statistically significant (P<0.05).The KPS score of the observation group was higher than that of the control group [(83.45±6.14) points vs (76.58±6.85) points], the difference was statistically significant (P<0.05).VEGF and HIF-1α in the observation group were lower than those in the control group,the difference was statistically significant (P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups (P>0.05).Conclusion Endo combined with cisplatin intrapleural perfusion in the treatment of non-small cell lung cancer malignant pleural effusion has a definite short-term curative effect. It can effectively eliminate the patient’s pleural effusion and improve the patient’s ability to take care of themselves without serious adverse reactions.

参考文献/References:

[1]徐敏,陈永发,胡建新.恩度联合顺铂胸腔内灌注治疗非小细胞肺癌大量恶性胸腔积液的临床观察[J].广东医科大学学报,2020,38(2):178-180. [2]李业锦.不同剂量恩度联合顺铂胸腔灌注治疗非小细胞肺癌恶性胸腔积液的临床分析[J].吉林医学,2019,40(5):928-929. [3]Hiranuma O,Uchino J,Yamada T,et al.Rationale and Design of a Phase Ⅱ Trial of Osimertinib Combined With Bevacizumab in Patients With Untreated Epidermal Growth Factor Receptor-mutated Non-small-cell Lung Cancer and Malignant Pleural and/or Pericardial Effusion (SPIRAL II Study) [J].Clin Lung Cancer,2019,20(3):e402-e406. [4]郑文慧,米虽才,陈志明.安罗替尼联合恩度或顺铂胸腔灌注治疗非小细胞肺癌恶性胸腔积液的临床研究[J].中国现代医生,2020,58(13):76-79. [5]李铭,胡广原,梅齐,等.不同剂量恩度联合顺铂腔内灌注治疗非小细胞肺癌恶性胸腔积液患者疗效及不良反应的差异[J].中国医药导刊,2017,19(8):791-793. [6]Cheng Y,Huang N,Qin K,et al.Comparison of intra-pleural injection efficacy between Endostar and Bevacizumab combined with pemetrexed/cisplatin for the treatment of malignant pleural effusion in patients with epidermal growth factor receptor-/anaplastic lymphoma kinase-lung adenocarci[J].Oncology and Translational Medicine,2019,5(2):53-57. [7]陈亚翔,霍悦,贾友超,等.恩度联合顺铂胸腔热灌注治疗非小细胞肺癌胸腔积液效果观察[J].山东医药,2017,57(18):38-40. [8]Shojaee S,Singh I,Solsky I,et al.Malignant Pleural Effusion at Presentation in Patients with Small-Cell Lung Cancer[J].Respiration,2019,98(3):1-5. [9]李业锦.不同剂量恩度联合顺铂胸腔灌注治疗非小细胞肺癌恶性胸腔积液的临床分析[J].吉林医学,2019,40(05):928-929. [10]何娟,缑剑,翟梅,等.恩度联合顺铂胸膜腔内局部给药治疗非小细胞肺癌恶性胸腔积液的疗效评价[J].国际呼吸杂志,2016,36(15):1127-1130. [11]Wang XJ,Miao K,Luo Y,et al.Randomized controlled trial of endostar combined with cisplatin/ pemetrexed chemotherapy for elderly patients with advanced malignant pleural effusion of lung adenocarcinoma[J].Journal of Buon,2018,23(1):92-97. [12]文雪梅.洛铂联合恩度胸腔灌注治疗非小细胞肺癌合并恶性胸腔积液的临床研究[J].国际呼吸杂志,2018,38(22):1694-1697. [13]余浪.恩度联合顺铂治疗非小细胞肺癌恶性胸腔积液的疗效观察[J].医学临床研究,2016,33(6):1135-1137. [14]韩忠诚,马丽丽,柳江,等.恩度联合顺铂腔内灌注治疗非小细胞肺癌合并恶性胸腔积液30例疗效观察[J].重庆医学,2017(A03):96-97.

相似文献/References:

[1]刘 贝,郑 慧,周 旺,等.3D-STI联合心脏综合指数评价肺癌患者GP化疗方案的隐匿性心肌毒性[J].医学信息,2019,32(08):100.[doi:10.3969/j.issn.1006-1959.2019.08.029]
　LIU Bei,ZHENG Hui,ZHOU Wang,et al.Evaluation of Occult Myocardial Toxicity in GP Chemotherapy Regimen of Lung Cancer Patients by 3D-STI Combined with Cardiac Comprehensive Index[J].Medical Information,2019,32(11):100.[doi:10.3969/j.issn.1006-1959.2019.08.029]
[2]张秀芳,陈 萍.安罗替尼联合顺铂治疗晚期卵巢癌恶性腹腔积液的疗效观察[J].医学信息,2019,32(18):132.[doi:10.3969/j.issn.1006-1959.2019.18.044]
　ZHANG Xiu-fang,CHEN Ping.Efficacy of Erlotinib Combined with Cisplatin in the Treatment of Advanced Ovarian Cancer with Malignant Ascites[J].Medical Information,2019,32(11):132.[doi:10.3969/j.issn.1006-1959.2019.18.044]
[3]李菡旖.顺铂同步放化疗方案治疗中晚期宫颈癌的疗效[J].医学信息,2019,32(24):103.[doi:10.3969/j.issn.1006-1959.2019.24.034]
　LI Han-yi.Efficacy of Cisplatin Concurrent Chemoradiotherapy for Advanced Cervical Cancer[J].Medical Information,2019,32(11):103.[doi:10.3969/j.issn.1006-1959.2019.24.034]
[4]任勇军,闵旭立,徐 浩,等.洛铂联合表柔比星化疗栓塞治疗原发性肝细胞癌的疗效[J].医学信息,2019,32(24):43.[doi:10.3969/j.issn.1006-1959.2019.24.014]
　REN Yong-jun,MIN Xu-li,XU Hao,et al.Efficacy of Loplatin Combined with Epirubicin Chemotherapy and Embolization for Primary Hepatocellular Carcinoma[J].Medical Information,2019,32(11):43.[doi:10.3969/j.issn.1006-1959.2019.24.014]
[5]李 博.紫杉醇加顺铂治疗晚期老年非小细胞癌的疗效[J].医学信息,2020,33(10):153.[doi:10.3969/j.issn.1006-1959.2020.10.045]
　LI Bo.Paclitaxel Plus Cisplatin in the Treatment of Advanced Elderly Non-small Cell Carcinoma[J].Medical Information,2020,33(11):153.[doi:10.3969/j.issn.1006-1959.2020.10.045]
[6]何显阳,刘方文,黄云英,等.多西他赛联合顺铂新辅助化疗对非小细胞肺癌治疗中相关肿瘤标记物的影响[J].医学信息,2021,34(23):165.[doi:10.3969/j.issn.1006-1959.2021.23.050]
　HE Xian-yang,LIU Fang-wen,HUANG Yun-ying,et al.Effect of Docetaxel Combined with Cisplatin Neoadjuvant Chemotherapy on Related Tumor Markers in the Treatment of Non-small Cell Lung Cancer[J].Medical Information,2021,34(11):165.[doi:10.3969/j.issn.1006-1959.2021.23.050]
[7]张书林,黄盛源,刘忠林,等.吉西他滨和多西他赛联合顺铂治疗晚期非小细胞肺鳞癌的效果比较[J].医学信息,2021,34(24):141.[doi:10.3969/j.issn.1006-1959.2021.24.036]
　ZHANG Shu-lin,HUANG Sheng-yuan,LIU Zhong-lin,et al.Comparison of Gemcitabine and Docetaxel Combined with Cisplatin in the Treatment of Advanced Non-small Cell Lung Squamous Cell Carcinoma[J].Medical Information,2021,34(11):141.[doi:10.3969/j.issn.1006-1959.2021.24.036]
[8]雷希君,罗利琼.腔内灌注治疗恶性胸腔积液的研究现状[J].医学信息,2024,37(03):184.[doi:10.3969/j.issn.1006-1959.2024.03.039]
　LEI Xi-jun,LUO Li-qiong.Research Status of Intracavitary Perfusion in the Treatment of Malignant Pleural Effusion[J].Medical Information,2024,37(11):184.[doi:10.3969/j.issn.1006-1959.2024.03.039]
[9]刘贤丰,李子俊.恩度联合培美曲塞与顺铂治疗晚期肺腺癌的临床效果观察[J].医学信息,2019,32(03):148.[doi:10.3969/j.issn.1006-1959.2019.03.048]
　LIU Xian-feng,LI Zi-jun.Clinical Observation of Endo Combined with Pemetrexed and Cisplatin in the Treatment of Advanced Lung Adenocarcinoma[J].Medical Information,2019,32(11):148.[doi:10.3969/j.issn.1006-1959.2019.03.048]

更新日期/Last Update: 1900-01-01